{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:44:36Z","timestamp":1790109876609,"version":"4.0.1"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.1001\/jamaoncol.2021.3971","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T15:07:09Z","timestamp":1631804829000},"page":"1678","source":"Crossref","is-referenced-by-count":49,"title":["Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma"],"prefix":"10.1001","volume":"7","author":[{"given":"Dickran","family":"Kazandjian","sequence":"first","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Multiple Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hill","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dew","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Hematology-Oncology Department, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candis","family":"Morrison","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Roswarski","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Hematology-Oncology Department, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Emanuel","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Petrosyan","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Levine Cancer Institute, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Calvo","sequence":"additional","affiliation":[{"name":"Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Dulau-Florea","sequence":"additional","affiliation":[{"name":"Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kwok","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Division of Hematology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Lindenberg","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Manasanch","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Maric","sequence":"additional","affiliation":[{"name":"Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mena","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Patel","sequence":"additional","affiliation":[{"name":"Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Tageja","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane B.","family":"Trepel","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Wang","sequence":"additional","affiliation":[{"name":"Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Yuan","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Braylan","sequence":"additional","affiliation":[{"name":"Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Choyke","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics & Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Sr","given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Multiple Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"coi210060r1","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"9","key":"coi210060r2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma.","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"25","key":"coi210060r3","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"coi210060r4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"6","key":"coi210060r5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"7","key":"coi210060r6","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"20","key":"coi210060r7","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma.","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"2","key":"coi210060r8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study.","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"2","key":"coi210060r9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.seminoncol.2019.03.001","article-title":"State of the science in smoldering myeloma: should we be treating in the clinic?","volume":"46","author":"Hill","year":"2019","journal-title":"Semin Oncol"},{"issue":"5","key":"coi210060r10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"coi210060r11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma.","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi210060r12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"coi210060r13","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","article-title":"Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial.","volume":"4","author":"Kazandjian","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"coi210060r14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma.","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"coi210060r15","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"coi210060r16","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi210060r18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"10","key":"coi210060r19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"5","key":"coi210060r20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"40","key":"coi210060r21","first-page":"1","article-title":"Clinical controversies in the management of smoldering multiple myeloma.","volume":"40","author":"Lomas","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"coi210060r22","author":"Mateos","year":"2019","journal-title":"Blood"},{"key":"coi210060r23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-142584","article-title":"Aggressive smoldering curative approach evaluating novel therapies (ASCENT): a phase 2 trial of induction, consolidation and maintenance in subjects with high risk smoldering multiple myeloma (SMM): initial analysis of safety data.","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"issue":"1","key":"coi210060r24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of discordance among smoldering multiple myeloma risk models.","volume":"7","author":"Hill","year":"2021","journal-title":"JAMA Oncol"},{"key":"coi210060r25","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.4659","article-title":"Moving from cancer burden to cancer genomics for smoldering myeloma: a review.","author":"Maura","year":"2020","journal-title":"JAMA Oncology"},{"issue":"1","key":"coi210060r26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"coi210060r27","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"key":"coi210060r17","unstructured":"National Cancer Institute. Cancer therapy evaluation program. Accessed March 4, 2021. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2783765\/jamaoncology_kazandjian_2021_oi_210060_1636656347.71522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T16:48:30Z","timestamp":1637254110000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2783765"}},"subtitle":["A Phase 2 Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.3971","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}